128 related articles for article (PubMed ID: 32343734)
1. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
Sakai M; Tokunaga S; Kawai M; Murai M; Kobayashi M; Kitayama T; Saeki S; Kawata T
PLoS One; 2020; 15(4):e0232428. PubMed ID: 32343734
[TBL] [Abstract][Full Text] [Related]
2. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.
Sharma S; Kumar S; Tomar MS; Chauhan D; Kulkarni C; Rajput S; Sadhukhan S; Porwal K; Guha R; Shrivastava A; Gayen JR; Kumar N; Chattopadhyay N
Bone; 2024 Aug; 185():117126. PubMed ID: 38777312
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism.
Ni Z; Liang X; Wu CC; Jin K; Kim YL; Lu KC; Chan TM; Fukagawa M; Kinoshita J; Nagai C; Kojima M; Yu X;
Kidney Int Rep; 2023 Nov; 8(11):2294-2306. PubMed ID: 38025238
[TBL] [Abstract][Full Text] [Related]
4. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.
Cozzolino M; Galassi A; Conte F; Mangano M; Di Lullo L; Bellasi A
Ther Clin Risk Manag; 2017; 13():679-689. PubMed ID: 28615947
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects.
He X; Narushima K; Kojima M; Nagai C; Li K
Drug Des Devel Ther; 2024; 18():567-581. PubMed ID: 38436038
[TBL] [Abstract][Full Text] [Related]
6. Mathematical Models of Parathyroid Gland Biology: Complexity and Clinical Use.
Schappacher-Tilp G; Kotanko P; Pirklbauer M
Front Nephrol; 2022; 2():893391. PubMed ID: 37674998
[TBL] [Abstract][Full Text] [Related]
7. The role of the calcium-sensing receptor in the pathophysiology of secondary hyperparathyroidism.
Riccardi D; Martin D
NDT Plus; 2008 Jan; 1(Suppl 1):i7-i11. PubMed ID: 25983956
[TBL] [Abstract][Full Text] [Related]
8. Misdiagnosis of chronic kidney disease and parathyroid hormone testing during the past 16 years.
Liu H; Zhao H; Zheng D; He W; Liu Y; Jin J; He Q; Lin B
Sci Rep; 2023 Sep; 13(1):15838. PubMed ID: 37739989
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals transdifferentiation of parathyroid chief cells into oxyphil cells in patients with uremic secondary hyperparathyroidism.
Mao J; You H; Wang M; Ba Y; Qian J; Cheng P; Lu C; Chen J
Kidney Int; 2024 Mar; 105(3):562-581. PubMed ID: 38142040
[TBL] [Abstract][Full Text] [Related]
10. Extended-Release Calcifediol: A Data Journey From Phase 3 Studies to Real-world Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism.
Merante D; Schou H; Morin I; Manu M; Ashfaq A; Bishop C; Strugnell S
Nephron; 2024 Apr; ():. PubMed ID: 38657576
[TBL] [Abstract][Full Text] [Related]
11. Secondary Hyperparathyroidism and Cognitive Decline.
Crepeau P; Fedorova T; Morris-Wiseman LF; Mathur A
Curr Transplant Rep; 2023 Jun; 10(2):60-68. PubMed ID: 38707996
[TBL] [Abstract][Full Text] [Related]
12. Reversal of complete atrioventricular block in dialysis patients following parathyroidectomy: A case report.
Xu SS; Hao LH; Guan YM
World J Clin Cases; 2024 Mar; 12(7):1313-1319. PubMed ID: 38524519
[TBL] [Abstract][Full Text] [Related]
13. Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.
Bolasco P
Clin Cases Miner Bone Metab; 2009 Sep; 6(3):210-9. PubMed ID: 22461248
[TBL] [Abstract][Full Text] [Related]
14. Silicon-Rhodamine Functionalized Evocalcet Probes Potently and Selectively Label Calcium Sensing Receptors
Bátora D; Fischer JP; Kaderli RM; Varga M; Lochner M; Gertsch J
ACS Pharmacol Transl Sci; 2024 May; 7(5):1557-1570. PubMed ID: 38751613
[TBL] [Abstract][Full Text] [Related]
15. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data.
Hedgeman E; Lipworth L; Lowe K; Saran R; Do T; Fryzek J
Int J Nephrol; 2015; 2015():184321. PubMed ID: 25918645
[TBL] [Abstract][Full Text] [Related]
16. The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs.
Tokunaga S; Kawata T
PLoS One; 2021; 16(1):e0245785. PubMed ID: 33481922
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease.
Rodríguez-Ortiz ME; Rodríguez M
F1000Res; 2020; 9():. PubMed ID: 32913635
[TBL] [Abstract][Full Text] [Related]
18. Development of evocalcet for unmet needs among calcimimetic agents.
Hamano N; Endo Y; Kawata T; Fukagawa M
Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
